BioSpace News Archive

BioSig Technologies, Inc.’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced the addition of Professor Angus Dalgleish to its Scientific Advisory Board (SAB).

Cognate BioServices, Inc., the premier contract development and manufacturing organization specializing in cell and cell-mediated gene therapy products, announced the launch of its new corporate brand identity, redesigned logo, and website across its portfolio of services and companies.

University of Minnesota’s Dr. Sara Hamman Osum Recognized with the 2020 Boehringer Ingelheim Veterinary Graduate Award and Megan Fahey from Cornell University Receives the 2020 Boehringer Ingelheim Veterinary Research Scholar Award

PRIMED Medical Products (PRIMED) has today announced its intent to establish a new major medical manufacturing facility in Canada.

Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day virtually over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to approximately 4:00 p.m. EDT and Tuesday, September 15, 2020 from 10:00 a.m. EDT to approximately 1:00 p.m. EDT.

- Reported responses in multiple solid tumor types during ASCO with updates at upcoming congresses in Q4 - - Continued progress toward launch of ADP-A2M4 for sarcoma in the US in 2022 with ongoing enrollment of patients in SPEARHEAD-1 - - Granted access to PRIority MEdicines (PRIME) regulatory support by the European Medicines Agency for ADP-A2M4 for the treatment of synovial sarcoma - - Completed public offering with net proceeds of approximately $244m; guidance confirmed: funded into 2022

Cabaletta Bio, Inc., a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, announced financial results for the second quarter ended June 30, 2020 and provided a business update.

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Monday August 10, 2020 at 8:30 AM ET to discuss results for the second quarter of 2020 and provide a business outlook for the remainder of the year. Michael S. Weiss, Executive Chairman and Chief Executive Officer, will host the call.

Mind Medicine Inc., the leading psychedelic pharmaceutical company, has engaged renowned psychedelic assisted therapy expert Dr. Peter Gasser as an advisor to its LSD experiential therapy program Project Lucy.

Greene to Pursue New Opportunities at End-Q3, While Remaining a Consultant for Up to Two Years to Ensure Orderly Transition